Navigation Links
Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
Date:10/20/2009

BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.

"Our LiverPool product is a great example of Celsis IVT's pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process," said Judy Madden, vice president of strategic development for Celsis. "We're proud that the US Patent Office has recognized our continued innovation and awarded us this patent."

Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at www.celsis.com/liverpool.

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt for more information.

About Celsis International

Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit www.celsis.com.

SOURCE Celsis International


'/>"/>
SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chicago-Based Celsis International Goes Private
2. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
3. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
4. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
5. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. Peripheral Artery Disease (PAD) Patent Granted to Dimera
8. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
9. Delcath Systems Granted Third Orphan Drug Designation
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 --> ... "Company") (OTCQB: PSID), a life sciences company focused ... Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact ... in January 2016, including entering into agreements with ... sales growth, and establishing several near-term pipeline opportunities. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... 150 years, continues today to pursue the highest level of accuracy and quality ... the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
(Date:2/10/2016)... 2016 Early-career researchers from ... , Uganda and Yemen ... and nutrition   Indonesia , Nepal ... and Yemen are being honored for their accomplishments ... also celebrated for mentoring young women scientists who are pursuing careers in ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016   Parabon NanoLabs ... U.S. Army Research Office and the Defense Forensics ... sensitivity of the company,s Snapshot Kinship Inference ... and, more generally, defense-related DNA forensics.  Although Snapshot ... (predicting appearance and ancestry from DNA evidence), it ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
Breaking Biology News(10 mins):